'Vote like Canada depends on it,' Carney says at Calgary rally ahead of Alberta referendum - CBC

Paulo Kawanishi is a Brazilian freelance writer and contributor on Polygon. He's been writings guides, features, and reviews since 2022 for publications like Eurogamer, Game Informer, Nintendo Life, PCGamesN, and Into the Spine. He's part of the guides team at Polygon, working on projects that cover from long explaners to quick tips on how to complete specific tasks in games. In addition, he also writes features, analysis, and reviews especially about JRPGs and games like Path of Exile 2. He holds a master's degree and a Ph. D. in Applied Linguistics. The symbol of older, more exciting times

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.

Willa Rowe is a contributing writer at Polygon, covering games and entertainment. She is a New York-based journalist and critic whose work has been featured in Kotaku, Digital Trends, the A. V. Club, GamesRadar+, and more. She also co-hosts the Girl Mode podcast. GRRM's prequel to the HBO series will continue

The new treatment kills off a sub-group of fat cells. (Jian Fan/iStockphoto/Getty Images) Early clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off. The drug here is CBL-514, which is administered via injection. As well as proving effective at reducing subcutaneous fat (just below the skin), there's evidence it can also reduce visceral fat (stored deeper around the organs). According to the team behind the trials, CBL-514 and its unconventional strategy have the potential to reduce fat in key areas of the body – with further benefits that come with weight loss likely to follow. "We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss," says endocrinologist Timothy Garvey, from the University of Alabama at Birmingham, who headed up the trial.